Related Experiment Video
Updated: Nov 3, 2025
03:40
Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
Published on: December 8, 2023
1.4K
2019-2020 Drug Updates in Hematologic Malignancies
1Mayo Clinic, Rochester, Minnesota.
Journal of the Advanced Practitioner in Oncology
|June 4, 2021
Insights
This review covers new medications for hematologic malignancies approved between late 2019 and late 2020. It details their pharmacology, clinical trial data, and adverse events for healthcare professionals.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- The landscape of hematologic malignancy treatment is rapidly evolving.
- New therapeutic agents are continuously being developed and approved.
Purpose of the Study:
- To review medications for hematologic malignancies approved from late 2019 to late 2020.
- To discuss the pharmacology, indications, clinical trial data, and adverse events of these new agents.
Main Methods:
- A review of recent literature and FDA approvals.
- Presentation of key clinical trial findings and safety profiles.
Main Results:
- Several novel medications were approved for hematologic malignancies during the specified period.
- These agents offer new treatment options with distinct pharmacological profiles.
Conclusions:
- Understanding the pharmacology, efficacy, and safety of newly approved medications is crucial for optimal patient management.
- Continuous education on emerging therapies is essential for healthcare providers in hematology and oncology.
Abstract:
During JADPRO Live Virtual 2020, Heidi D. Finnes, PharmD, BCOP, FHOPA, discussed the pharmacology and indications of medications approved from late 2019 to late 2020 for the management of patients with hematologic malignancies, reviewed pivotal clinical trial data, and covered the adverse events of these hematologic medications.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
603
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
603
01:21Hematopoiesis
7.4K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
7.4K
01:01Regulation of Hematopoietic Stem Cells
3.6K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.6K
01:20Overview of Hematopoiesis
5.9K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
5.9K
02:49Cancer Therapies
8.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
01:28Role of Hematopoietic Growth Factors
2.3K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
2.3K